Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients

OBJECTIVE: Immunocompromised patients have an increased risk of a severe form of COVID-19. The clinical efficacy of the tixagevimab/cilgavimab monoclonal antibody combination as pre-exposure prophylaxis against BA.1 and BA.2 SARS-CoV-2 Omicron sublineages is unknown. We aimed to describe the inciden...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Yann, Flahault, Adrien, Chavarot, Nathalie, Melenotte, Cléa, Cheminant, Morgane, Deschamps, Paul, Carlier, Nicolas, Lafont, Emmanuel, Thomas, Marion, Flamarion, Edouard, Lebeaux, David, Charlier, Caroline, Rachline, Anne, Guérin, Corinne, Ratiney, Robert, Touchard, Justine, Péré, Hélène, Rozenberg, Flore, Lanternier, Fanny, Arlet, Jean-Benoît, Avouac, Jérôme, Boussaud, Véronique, Guillemain, Romain, Vignon, Marguerite, Thervet, Eric, Scemla, Anne, Weiss, Laurence, Mouthon, Luc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Research Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340091/
https://www.ncbi.nlm.nih.gov/pubmed/35926762
http://dx.doi.org/10.1016/j.cmi.2022.07.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340091/
https://www.ncbi.nlm.nih.gov/pubmed/35926762
http://dx.doi.org/10.1016/j.cmi.2022.07.015

Ejemplares similares